Pfizer’s Blockbuster Migraine Portfolio Plan On Track With Zavzpret Approval
Second Product From $11.6bn Biohaven Acquisition
Executive Summary
Pfizer plans to build on the momentum gained for its oral drug Nurtec ODT, now the leading CGRP inhibitor, with the intranasal Zavzpret, which will be priced in line with the rest of the class.
You may also be interested in...
Biohaven Makes Bet On Brain-Penetrant TYK2/JAK1 Inhibitor For Neurological Diseases
The company, which has struggled in the clinic following a deal where Pfizer bought its migraine portfolio, is licensing the dual inhibitor drug from a Chinese firm for up to $970m.
Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs
Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.
Biohaven Relaunches As Biohaven Ltd. After Pfizer Buyout Closes
As signaled when Pfizer acquired Biohaven’s Nurtec and CGRP assets, Biohaven will continue under a modified name, with a focus on epilepsy, obsessive compulsive disorder and spinal muscular atrophy.